MaxCyte (NASDAQ: MXCT) announced Tuesday that it has agreed to acquire Akron BioProducts for approximately $151.8 million, significantly expanding its position in the rapidly developing cell and gene therapy manufacturing market. The transaction is expected to nearly double MaxCyte’s revenue base while accelerating its path toward profitability.
The acquisition brings together two companies providing essential technologies and materials used in developing and manufacturing advanced cell therapies. MaxCyte specializes in cell-engineering platforms, while Akron Bio supplies critical manufacturing materials used throughout the cell therapy production process.
Under the agreement, MaxCyte will pay $105 million in cash, issue approximately 20.6 million shares valued at $26.8 million, and make an additional $20 million in guaranteed deferred payments during 2028 and 2029. The transaction is expected to close before the end of 2026, subject to customary conditions.
Akron Bio, headquartered in Boca Raton, Florida, supplies pharmaceutical-grade reagents and manufacturing materials used in cell therapy development. Its products include growth factors, cytokines, specialized media, and human plasma-derived materials that support the production of therapeutic cells.
The acquisition expands MaxCyte’s capabilities beyond its existing non-viral cell-engineering technology, allowing the combined company to support additional stages of the manufacturing process, including both viral and non-viral approaches.
For biotechnology developers, these materials are essential to producing consistent, high-quality cell therapies that meet regulatory requirements.
The combined business is expected to support more than 100 clinical programs and five commercially approved therapies, strengthening MaxCyte’s exposure to treatments already generating commercial manufacturing demand.
Akron Bio is projected to generate approximately $28 million in revenue and between $7 million and $8 million in earnings before interest, taxes, depreciation, and amortization (EBITDA) during 2026.
Importantly, Akron also brings positive cash flow and recurring revenue from manufacturing materials, potentially providing greater financial stability as MaxCyte expands its operations.
MaxCyte expects the combination to reduce annual cash burn to less than $10 million in 2027, compared with the higher spending typically associated with developing and commercializing emerging biotechnology platforms.
The company has also secured a credit facility of up to $75 million from MidCap Financial to help support the acquisition and future operations.
The announcement coincided with MaxCyte’s third-quarter earnings results, which showed revenue increasing 49% year over year to $10.2 million. Core business revenue rose 27%, while revenue from strategic platform licensing programs reached $2 million.
MaxCyte also raised its standalone full-year 2026 revenue guidance to at least $34.5 million, reflecting improving demand across its existing business.
For small-cap biotechnology investors, the transaction illustrates how companies can pursue growth by expanding beyond a single technology platform into complementary products and services.
Cell and gene therapies represent a growing area of medicine, but their development requires specialized equipment, manufacturing materials, and extensive regulatory oversight.
Companies supplying these essential components can potentially benefit from industry expansion without assuming all the clinical development risks associated with individual drug candidates.
The acquisition also creates opportunities for MaxCyte to introduce Akron’s products to existing customers, potentially increasing revenue from established relationships.
However, investors will need to monitor integration expenses, debt obligations, and shareholder dilution associated with the transaction.
The combined company is expected to have approximately $40 million to $45 million in cash and investments at closing, providing liquidity as management works toward profitability.
With more cell therapies advancing through clinical trials and into commercial production, MaxCyte is positioning itself to participate in a broader portion of the manufacturing process.
The acquisition marks a significant strategic shift for the company, transforming it from a specialized cell-engineering technology provider into a more comprehensive supplier supporting the development and commercialization of next-generation therapies.
